Residency · Residency · Otolaryngology
Thyroid Nodules and Well-Differentiated Thyroid Cancer
Overview
Thyroid nodules are extremely common, detected in up to 68% of the population on high-resolution ultrasound, yet only 5-15% harbor malignancy. Well-differentiated thyroid cancers (papillary and follicular) account for over 90% of thyroid malignancies. A systematic approach using ultrasound risk stratification, fine-needle aspiration cytology, and molecular testing guides surgical decision-making and long-term surveillance.
Epidemiology
Thyroid nodules palpable in 5% of women, 1% of men; much higher prevalence on ultrasound. Thyroid cancer incidence has tripled over the past three decades, largely due to incidental detection. Papillary thyroid carcinoma (PTC) accounts for 80-85% of thyroid malignancies. Follicular thyroid carcinoma (FTC) accounts for 10-15%. Overall excellent prognosis: 10-year disease-specific survival >95% for well-differentiated thyroid cancer. Risk factors: radiation exposure (childhood), family history, iodine deficiency (follicular), age extremes (<15, >45).
Ultrasound Risk Stratification
ACR TI-RADS (Thyroid Imaging Reporting and Data System)
Point-based system assessing five ultrasound features: Composition: cystic (0), spongiform (0), mixed cystic-solid (1), solid (2). Echogenicity: anechoic (0), hyperechoic/isoechoic (1), hypoechoic (2), very hypoechoic (3). Shape: wider-than-tall (0), taller-than-wide (3). Margin: smooth (0), ill-defined (0), lobulated/irregular (2), extrathyroidal extension (3). Echogenic foci: none/large comet tail (0), macrocalcifications (1), peripheral calcifications (2), punctate echogenic foci (3). TR1 (benign, 0 points): no FNA. TR2 (not suspicious, 2 points): no FNA. TR3 (mildly suspicious, 3 points): FNA if >= 2.5 cm; follow if >= 1.5 cm. TR4 (moderately suspicious, 4-6 points): FNA if >= 1.5 cm; follow if >= 1 cm. TR5 (highly suspicious, >= 7 points): FNA if >= 1 cm; follow if >= 0.5 cm.
Suspicious Ultrasound Features
Solid hypoechoic nodule, Microcalcifications (psammoma bodies in PTC), Taller-than-wide shape, Irregular margins or extrathyroidal extension. Abnormal cervical lymphadenopathy (round, loss of fatty hilum, cystic, microcalcifications, peripheral vascularity).
Fine-Needle Aspiration Cytology
Bethesda System for Reporting Thyroid Cytopathology
| Bethesda Category | Diagnosis | Malignancy Risk | Recommended Management |
|---|---|---|---|
| I | Non-diagnostic / Unsatisfactory | 1-4% | Repeat FNA |
| II | Benign | 0-3% | Follow with ultrasound |
| III | AUS / FLUS | 6-18% | Repeat FNA, molecular testing, or lobectomy |
| IV | Follicular neoplasm / Suspicious for FN | 10-40% | Lobectomy or molecular testing |
| V | Suspicious for malignancy | 45-75% | Lobectomy or total thyroidectomy |
| VI | Malignant | 97-99% | Surgery based on extent |
Bethesda I: Non-diagnostic/unsatisfactory (1-4% malignancy risk); repeat FNA. Bethesda II: Benign (0-3% risk); follow with ultrasound. Bethesda III: Atypia of undetermined significance / follicular lesion of undetermined significance (AUS/FLUS) (6-18% risk); repeat FNA, molecular testing, or lobectomy. Bethesda IV: Follicular neoplasm / suspicious for follicular neoplasm (10-40% risk); lobectomy or molecular testing. Bethesda V: Suspicious for malignancy (45-75% risk); lobectomy or total thyroidectomy. Bethesda VI: Malignant (97-99% risk); surgery based on extent of disease.
Molecular Testing
Used primarily for Bethesda III and IV to refine cancer probability. Afirma Gene Sequencing Classifier (GSC): rule-out test; "benign" result has high negative predictive value (94-96%). ThyroSeq v3: rule-in and rule-out; tests for multiple gene mutations and fusions; high sensitivity and specificity. Key mutations: BRAF V600E (most common in PTC, 40-60%), RAS mutations (follicular variant PTC, FTC), RET/PTC rearrangements, PAX8/PPARgamma (FTC). BRAF V600E + TERT promoter mutation combination confers more aggressive behavior.
Pathology of Well-Differentiated Thyroid Cancer
Papillary Thyroid Carcinoma
Most common thyroid malignancy. Characteristic features: papillary architecture, Orphan Annie eye nuclei, nuclear grooves, intranuclear pseudoinclusions, psammoma bodies. Variants: classical, follicular variant (NIFTP reclassification), tall cell (aggressive), diffuse sclerosing, columnar cell, hobnail. Lymphatic spread is common (30-80% have nodal metastases), Multifocality in 20-80%, Hematogenous metastases rare (lung, bone).
Follicular Thyroid Carcinoma
Cannot be diagnosed on FNA (requires capsular/vascular invasion on final pathology). Minimally invasive: capsular invasion only; excellent prognosis. Widely invasive: vascular invasion; worse prognosis. Hematogenous spread (lung, bone) more common than lymphatic. Hurthle cell carcinoma: now classified separately; less avid for radioactive iodine.
Surgical Management
Lobectomy
Appropriate for: Bethesda III/IV nodules when molecular testing not performed or indeterminate. Unifocal PTC 1-4 cm without extrathyroidal extension, clinically negative nodes, no prior radiation, no distant metastases. Low-risk follicular carcinoma (minimally invasive without vascular invasion). Advantages: lower complication rate, avoids permanent thyroid hormone replacement in ~50%. Completion thyroidectomy may be needed if final pathology shows high-risk features.
Total Thyroidectomy
Indications: Tumors >4 cm. Gross extrathyroidal extension. Bilateral disease or multifocal disease. Clinically apparent nodal metastases (cN1). Distant metastases. Patient desires radioactive iodine therapy or facilitated surveillance with thyroglobulin. Prior radiation history. Risks: recurrent laryngeal nerve injury (1-2% permanent), hypoparathyroidism (1-2% permanent).
Central Neck Dissection
Therapeutic: for clinically or radiographically apparent central compartment disease (cN1a). Prophylactic: controversial; may improve staging accuracy and reduce recurrence but increases hypoparathyroidism risk. ATA recommends prophylactic central neck dissection for advanced primary tumors (T3/T4) or clinically involved lateral neck nodes.
Radioactive Iodine (RAI) Therapy
Not recommended for ATA low-risk: unifocal T1-T2, N0, M0 without aggressive histology. May favor: ATA intermediate-risk (microscopic ETE, minor vascular invasion, small nodal metastases, aggressive histology). Recommended: ATA high-risk (gross ETE, large nodal metastases, distant metastases, incomplete resection). Typical dose: 30-100 mCi (adjuvant/remnant ablation), 100-200 mCi (treatment of metastatic disease). Requires TSH stimulation: thyroid hormone withdrawal or recombinant human TSH (Thyrogen). Low-iodine diet for 1-2 weeks before RAI.
Thyroglobulin Surveillance
Thyroglobulin (Tg) is the tumor marker for well-differentiated thyroid cancer after total thyroidectomy. Unstimulated Tg <0.2 ng/mL indicates excellent response, Rising Tg indicates recurrence. Anti-Tg antibodies can interfere with Tg assays; trending antibody levels useful. Stimulated Tg (with TSH elevation) increases sensitivity for detecting residual disease. Neck ultrasound at 6-12 months post-surgery, then periodically.
ATA Risk Stratification (Dynamic)
Low risk: intrathyroidal, classical PTC, no vascular invasion, cN0, R0, no RAI uptake outside thyroid bed. Intermediate risk: microscopic ETE, RAI uptake in neck outside thyroid bed, aggressive histology, minor vascular invasion, cN1a with small nodes. High risk: gross ETE (T4), incomplete resection, distant metastases, large nodal metastases, follicular with extensive vascular invasion. Dynamic risk stratification reclassifies risk based on response to initial therapy.
<image>ACR TI-RADS ultrasound classification chart showing the five feature categories (composition, echogenicity, shape, margin, echogenic foci) with point assignments for each finding. Side panels display representative ultrasound images for each TI-RADS category (TR1-TR5) with corresponding FNA size thresholds. A benign spongiform nodule is shown for TR2, a mildly hypoechoic nodule for TR3, a hypoechoic nodule with irregular margins for TR4, and a very hypoechoic solid nodule with microcalcifications and taller-than-wide shape for TR5.</image>
<image>Bethesda System for thyroid cytopathology showing representative cytology images for each category (I-VI). Bethesda II shows benign colloid nodule with sheets of follicular cells and abundant colloid. Bethesda III shows atypical cells with nuclear features borderline for PTC. Bethesda IV shows microfollicular pattern without colloid. Bethesda V shows cells suspicious for PTC with nuclear grooves and pale chromatin. Bethesda VI shows classic PTC with papillary clusters, intranuclear pseudoinclusions, and psammoma bodies. Each category includes the implied risk of malignancy and recommended management.</image>
<image>Surgical decision-making algorithm for thyroid nodules. Flowchart begins with thyroid nodule detected, proceeds through ultrasound risk stratification, FNA based on TI-RADS criteria, Bethesda classification, molecular testing for indeterminate results, and branches to lobectomy vs. total thyroidectomy based on tumor size, risk features, and patient preference. Post-surgical pathway shows RAI consideration and dynamic risk stratification for long-term surveillance.</image>
Clinical Pearls
Most thyroid nodules are benign; the primary role of the otolaryngologist is to identify the 5-15% that harbor malignancy through systematic ultrasound and FNA evaluation. BRAF V600E mutation is the most common genetic alteration in PTC and is associated with more aggressive behavior, particularly when co-occurring with TERT promoter mutations. Molecular testing (Afirma GSC, ThyroSeq) has significantly reduced the rate of diagnostic lobectomies for Bethesda III/IV nodules. Lobectomy is increasingly favored for low-risk, unifocal PTC 1-4 cm, avoiding the complications of total thyroidectomy while maintaining excellent oncologic outcomes. Thyroglobulin is an excellent tumor marker after total thyroidectomy, but anti-Tg antibodies must always be checked simultaneously as they can cause falsely low Tg values. Dynamic risk stratification allows de-escalation of surveillance intensity for patients showing excellent response to initial therapy.
References
- Haugen BR, Alexander EK, Bible KC, et al. "2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer." Thyroid. 2016;26(1):1-133.
- Tessler FN, Middleton WD, Grant EG, et al. "ACR Thyroid Imaging, Reporting and Data System (TI-RADS)." J Am Coll Radiol. 2017;14(5):587-595.
- Cibas ES, Ali SZ. "The 2017 Bethesda System for Reporting Thyroid Cytopathology." Thyroid. 2017;27(11):1341-1346.
- Steward DL, Carty SE, Sippel RS, et al. "Performance of a Multigene Genomic Classifier in Thyroid Nodules with Indeterminate Cytology." JAMA Oncol. 2019;5(2):204-212.
